We are live on ! Find out more
BCTX icon

BriaCell Therapeutics

25 hedge funds and large institutions have $379K invested in BriaCell Therapeutics in 2024 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,900% more call options, than puts

Call options by funds: $90K | Put options by funds: $3K

123% more capital inflows, than outflows

Capital inflows: $274K | Capital outflows: $123K

100% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 4

19% more funds holding

Funds holding: 21 → 25 (+4)

1.24% more ownership

Funds ownership: 2.45% → 3.69% (+1.2%)

0% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 6

Holders
25
Holders Change
+4
Holders Change %
+19.05%
% of All Funds
0.33%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
6
Reduced
6
Closed
4
Calls
$90​K
Puts
$3​K
Net Calls
+$87​K
Net Calls Change
-⁠$70​K

BCTX Hedge Fund Activity: Q4 2024 in Review

25 of the 7,628 institutional investors tracked by Wall St. Rank reported a position in BriaCell Therapeutics (BCTX) for Q4 2024, worth a combined $379K — down 30% from $538K a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new BCTX positions and 4 closed out — a net gain of 4 holders — while 6 added to existing stakes and 6 trimmed.

The largest buyer was Cantor Fitzgerald, opening a new position worth an estimated $44.7K. The largest seller was Summit Trail Advisors, exiting entirely with an estimated $43.4K sold.

  • 25 institutional investors held BriaCell Therapeutics (BCTX) as of Q4 2024, up from 21 in Q3 2024.
  • Funds reported $379K of BriaCell Therapeutics stock for Q4 2024, down 30% quarter-over-quarter.
  • 8 funds opened new BriaCell Therapeutics positions in Q4 2024 and 4 closed out, a net change of +4 holders.
  • The largest BriaCell Therapeutics buyer in Q4 2024 was Cantor Fitzgerald, an estimated $44.7K added.
  • The largest BriaCell Therapeutics seller in Q4 2024 was Summit Trail Advisors, an estimated $43.4K sold.

Based on aggregated 13F filings for Q4 2024.